Ridaforolimus (Deforolimus AP23573) BEZ235 SF1126 XL418 XL765 XL147 Everolimus (RAD001) PX-866 XL281 Perifosine XL228 RDEA119 GDC-0941 bismesylate PF-04691502 GDC-0973 Sirolimus (Rapamune) GDC-0980 Temsirolimus (Torisel, CCI-779) Selumetinib (AZD6244)

PX-866 is an inhibitor of PI3K under development by Oncothyreon.  For information at the manufacturer's website link here.

A Phase I trial of oral PX-866 has opened in 2008.  See clinicaltrials.gov link NCT00726583.